Crossmark

Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

Crossref DOI link: https://doi.org/10.1136/jitc-2023-008482

Published Online: 2024-03-21

Published Print: 2024-03

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Hu, Xizi https://orcid.org/0009-0000-2192-6185
Bukhari, Shoiab M

Tymm, Carly

Adam, Kieran

Lerrer, Shalom

Henick, Brian S https://orcid.org/0000-0003-2681-0805
Winchester, Robert J

Mor, Adam
Funding

Funding for this research was provided by:

NIH (AI125640)

NIH (AI150597)

NIH (AI175498)

NIH (CA231277)

NIH (S10OD030282)
License Information

License valid from 2024-03-22